AI-generated · cited to primary sources · not investment advice
Indegene (544172) Nov 2025 Filing Analysis
Does management do what it says?
The delivery headcount with healthcare expertise reached 24.8%, slightly exceeding the upper bound of the previously guided range. (3 exceeded, 2 met across 5 tracked commitments)
“But we certainly are looking forward to a growth rate, which is higher than what we saw in the past year and even the start of this year.”
The Tectonic offering is showing early traction, doubling its customer count from 2 in Q1 to 4 in Q2 and clocking $2 million in revenue for H1 FY26. (1 in progress, 1 met across 2 tracked commitments)
“Among the significant wins during the quarter, there were 2 large deals of 3 million-plus ACV... Both these are start expected to start in Q3 and ramp up over the next 3, 4 quarters. Additionally, we had 4 deal wins in the 1 million to 3 million ACV range.”
EBITDA margins remained flat quarter-on-quarter at 20.2%, meeting the guidance for stability. (2 met, 1 revised, 1 missed across 4 tracked commitments)
“These ahead of the curve investments should accelerate our growth progressively over 6 to 8 quarters, but with EBITDA margins compression in the near term by about 1.5%.”
See the full cited Management analysis of Indegene
What could break the thesis?
The risk is easing as management clarifies that new US policies (MFN pricing, TrumpRx, and tariffs) are less disruptive than initially feared, providing a 'template for moving forward.' (1 easing, 1 stable)
“Overall, this has been a big relief for the industry because it takes away the regulatory overhang and provides a template for moving forward in a way that is not significantly disruptive.”
See the full cited Risk analysis of Indegene
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.